Phosphatidylcholine-specific phospholipase C (PC-PLC) is an enzyme that catalyses the hydrolysis of phosphatidylcholine (PC), which is a phospholipid, into phosphocholine and diacylglycerol (Figure 1). PC-PLC has emerged as a novel target for the development of new anti-cancer drugs, as enhanced PC-PLC activity was observed during tumour progression. Interestingly, however, the identity of mammalian PC-PLC is not known to date. By using PC-PLC from Bacillus cereus (PC-PLCBc) as a model system, we report our progress in the development of new PC-PLC inhibitiors by using a combined structural and biophysical-based approach. We hope our study will enable the development of new anti-cancer agents, as well as facilitating our quest to identify mammalian PC-PLC (e.g. as chemical probe).
Figure.1: PC-PLC catalyses the conversion of phosphatidylcholine to phosphocholine and diaglycerol.